ARNA Related FDA
-
VIVUS, Inc. (VVUS) Pops as Larger Qsymia Retail Presence Expected Soon
-
Arena (ARNA) Confirms BELVIQ Will Soon Be Available for Sale in the U.S.
-
Arena (ARNA) Clears Final BELVIQ Marketing Hurdle; Could Make U.S. Debut in June
-
VIVUS, Inc. (VVUS) Ticks Higher as Arena (ARNA) Pulls BELVIQ MAA in Europe
-
Arena Pharmaceuticals (ARNA) Withdraws EU BELVIQ Application
-
Arena Pharma (ARNA) Commences APD334 Phase 1 for S1P1
-
Arena (ARNA) Reports Submission of BELVIQ Market App in Mexico
-
Arena (ARNA), VIVUS (VVUS) Face Uphill Obesity Battle as Costs Play Key Role
-
Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
-
VIVUS (VVUS) Cuts Qsymia Price by About 70%; Arena (ARNA) on Watch
-
Arena (ARNA) Will Need Lower Co-Payments, Broader Coverage for Belviq Success (VVUS)
-
Arena (ARNA): Eisai Discloses $199.50/Bottle Acquisition Cost of Belviq 10-mg Tabs
-
Risks vs. Benefits of Bariatric Surgery Might Put Obesity Pills in Lime Light (ARNA) (VVUS) (OREX)
-
VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
-
VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
-
Obesity Pill Makers in Focus as EMA CHMP Denies Belviq MAA (ARNA) (VVUS) (OREX)
-
Arena Pharma (ARNA) Receives Day 180 from CHMP for Belviq
-
Arena (ARNA) Chugs Higher on Volume; Will Present at JP Morgan Conf. Tomorrow
-
JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting
-
Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)
-
Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave
-
Arena Pharmaceuticals' (ARNA) Lorcaserin Proposed for DEA Schedule IV
-
VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
-
Arena Pharma (ARNA) Enters Marketing, Supply Agreement for Belviq
-
VIVUS (VVUS) Qsymia Prescriptions Remain High Amid Birth Defect Warning; Positive for Arena (ARNA)
-
Orexigen (OREX) Pops Higher as Contrave May Get Speedier Approval (VVUS) (ARNA)
-
Arena (ARNA) Runs Higher as VIVUS (VVUS) Seeks Broader Obesity Pill Distribution
-
Arena (ARNA) Partner Eisai May Also Have Promising Weight-Loss Pill in the Works
-
Arena Pharma (ARNA) Commences APD811 Phase 1
-
FDA Might Allow for Faster Approval of Obesity Drugs (VVUS) (ARNA) (OREX)
-
Arena (ARNA) Higher as Large PBM Joins Obesity Pill Distribution Network (VVUS)
-
VIVUS (VVUS) Lower Heading into Obesity 2012 Event; Will Present New Qsymia Data
-
VIVUS (VVUS) Gets Jump on Arena (ARNA); Quietly Discloses Qsymia Availability in U.S.
-
Arena Pharma (ARNA) Moves Higher; Sees European Belviq Approval in H113, All Debt Prepaid
-
VIVUS (VVUS), Arena (ARNA) Tick Higher on Positive Orexigen (OREX) News
-
Obesity Drug Makers Gears Up for Busy Sept. Conference Schedule (ARNA) (OREX) (VVUS)
-
Arena (ARNA), Orexigen (OREX) Lift With VIVUS (VVUS)
-
Arena (ARNA) Higher as VIVUS (VVUS) Downgrade is Company-Specific, Not Industry Issue
-
VIVUS (VVUS) Weighed-Down by Negative Report
-
VIVUS' (VVUS) Qsymia Approved and has Advantages Over Belviq
-
Orexigen (OREX) Higher Early Following VIVUS (VVUS) Qsymia Approval; Arena (ARNA) Lower
-
Just Minutes Left to Trade VIVUS (VVUS) Ahead of Expected FDA Approval
-
VIVUS (VVUS), Orexigen (OREX) Higher Ahead of PDUFA; Arena (ARNA) Lags
-
VIVUS (VVUS) In the Spotlight Ahead of Likely FDA Obesity Drug Approval
-
VIVUS (VVUS) Gets a Boost from Uber-Bullish Orexigen (OREX) Call
-
Orexigen (OREX), Arena (ARNA) Stronger into Qnexa PDUFA
-
With Plenty of Good Arguments for Both Bulls and Bears, VIVUS (VVUS) Qnexa Approval at 50/50 - Jefferies
-
Arena Pharma (ARNA) Files MAA for Lorcaserin with Swissmedic
-
Arena Pharma (ARNA) Dips; Enrollment Accelerated for Orexigen's (OREX) Contrave Trial
-
VIVUS (VVUS) Volatility Lower into PDUFA for Qnexa
Back to ARNA Stock Lookup
